BioLargo, Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF using an explicit turnaround cash-flow path: -$8.0M, -$5.0M, -$2.0M, $0.5M, $2.0M, $4.0M, $6.0M, $8.0M, $9.0M, $10.0M in years 1-10 (assuming new government/PFAS-remediation contracts scale the environmental-technology business toward profitability); 20% discount rate (going-concern doubt, steep recent revenue decline, heavy historical dilution); 3% terminal growth; ~$2.9M estimated net cash; 321.39M shares outstanding.

Reasoning: BioLargo is a micro-cap environmental-technology company with disclosed going-concern doubt and a 56% revenue decline in 2025, so the very low resulting per-share value (well below the current price) reflects a conservative, heavily risk-adjusted view of its turnaround prospects rather than an assumption that its patented CupriDyne/PFAS technologies have no value at all.